Genomic Testing of Tumors and Genetic Analysis in Cancer Patients Using Archived or Newly Collected Tissue and Blood Samples

What this Trial Is About

Researchers are studying genetic changes in cancer cells, focusing on mutations that may influence how cancer cells survive. The study aims to test cancer tumors for specific gene mutations using leftover tissue from prior surgeries or biopsies. Additionally, participants provide blood, cheek swab, or saliva samples to compare normal genes with tumor mutations. This observational study seeks to understand how tumor genes change over time and affect responses to experimental cancer treatments. The study includes molecular profiling of tumors through leftover or prospectively collected tissue samples analyzed in a certified laboratory. It also involves clinical germline analysis of normal DNA samples to detect inherited mutations linked to cancer risk. Participants in Part B may undergo minimal risk collections and research biopsies. The study uses advanced sequencing techniques such as whole genome and exome sequencing and examines genetic mechanisms of tumor development. Participants provide tumor tissue and normal gene samples, which are tested using various genetic assays. The team assesses the frequency of actionable mutations and evaluates how molecular profiling results influence patient treatment. Data is collected over time to explore genetic changes and tumor behavior. Safety and impact are monitored through research biopsies and clinical follow-up, with the study continuing until January 2027.

Genomic Profiling in Cancer Patients